Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4198 | Values Clarification and Attitudes Transformation (VCAT) Workshop Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This current protocol encompasses an investigator-blinded randomized exercise intervention in 10 COVID-19 survivors that have been discharged from hospital. The subjects will be randomized to perform three different exercise training protocols in a random order. The aim is to clarify the feasibility and safety of three training protocols in COVID-19 survivors. The hypothesis is that patients surviving COVID-19 will be able to comply to all training protocols.
Description: the 10-point Likert scale, which evaluates enjoyment and perceived tolerance of each training protocol at the end of each training session using a 10-point Likert scale, which is one of the most fundamental and frequently used psychometric tools in social science research. Patients have to indicate the degree to which they agreed with the following statement before training: "How motivated are you for today's training?" following two statements after the training: "How enjoyable have today´s training session been?" and "How tolerant has today´s training been?" A higher number describes better agreement.
Measure: 10-point Likert scale Time: Through study completion, an average of 3 monthsDescription: Percentage completed exercise of the total duration
Measure: Participant adherence to the training dose Time: Through study completion, an average of 3 monthsDescription: Percentage of the exercise session spent at a heart rate above 85% of maximal heart rate
Measure: Participant adherence to the training intensity Time: Through study completion, an average of 3 monthsDescription: Adverse effect which leads to termination of the exercise training, registered as a binary outcome (yes/no)
Measure: Adverse effects Time: Through study completion, an average of 3 monthsDescription: Verification of training intensity is evaluated by rate of perceived exertion after each interval (6-20 Borg scale) and after completed training (1-10 Borg scale), and from accumulated minutes in the predefined heart rate zones.
Measure: Rate of perceived exertion Time: The secondary outcome measure will be evaluated through study completion, an average of 3 monthsDescription: Functional capacity of the patients is another outcome which is assessed with the Post COVID-19 Functional scale, which is a scale to measure the consequence of the disease beyond binary outcomes. The scale ranges from 0-4, where 4 describes "worst functional limitation (worse outcome)".
Measure: Post COVID-19 Functional scale Time: The secondary outcome measure will be evaluated through study completion, an average of 3 monthsThe physical inactivity promoted by the patient's hospitalization, including those infected with the coronavirus, can lead to an important health impairment, including atrophy and loss of muscle function. Thus, a prospective study will be conducted to assess the effect of a home-based exercise training program on health outcomes and quality of life in COVID-19 survivors.
Description: Higher score means better outcome.
Measure: Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at 12 weeks. Time: Baseline and 12 weeks.Description: Higher score means worse outcome.
Measure: Change from baseline on fatigue evaluated by the fatigue severity scale at 12 weeks. Time: Baseline and 12 weeks.Description: Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides
Measure: Change from baseline on lipid profile at 12 weeks. Time: Baseline and 12 weeks.Description: Fasting serum concentrations of glucose and insulin.
Measure: Change from baseline on insulin sensitivity at 12 weeks. Time: Baseline and 12 weeks.Description: Higher score means worse outcome.
Measure: Change from baseline on anxiety symptoms assessed by Back Scale at 12 weeks. Time: Baseline and 12 weeks.Description: Higher score means worse outcome.
Measure: Change from baseline on depression symptoms assessed by Back Scale at 12 weeks. Time: Baseline and 12 weeks.Description: Higher score means worse outcome.
Measure: Change from baseline on functional status assessed by Post-COVID-19 Functional Status (PCFS) Scale at 12 weeks. Time: Baseline and 12 weeks.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports